Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Molina To Contact Him Directly To Discuss Their Options If you suffered losses in Molina between February 5, 2025 and July 23, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a lea ...

NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP reminds purchasers or acquirers of Molina Healthcare, Inc. (NYSE: MOH) (“Molina”) securities between February 5, 2025 and July 23, 2025 (the “Class Period”) have until December 2, 2025 to seek appointment as lead plaintiff. PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION The filed complaint alleges that Molina Healthcare and certain executives violated the Securities Exchange Act of 1934 by making materia ...

Core Viewpoint - A South Florida police pension fund and a European investment firm are seeking to be lead plaintiffs in a class-action lawsuit against Fiserv, alleging misleading statements regarding its Clover unit and significant financial losses due to share price declines [1][4]. Group 1: Lawsuit Details - The lawsuit was filed in July 2024, claiming Fiserv misled investors by not disclosing the forced migration of merchants to its Clover point-of-sale product during late 2023 to mid-2024 [4]. - The complaint names Fiserv and four executives, including current CEO Michael Lyons and former CEO Frank Bisignano, as defendants [5]. - The litigation targets investors who purchased or owned Fiserv stock between July 24, 2024, and July 22, 2025 [5]. Group 2: Financial Impact - The Hollywood police pension fund reported a loss of $1.67 million due to the decline in Fiserv shares, while Ethenea Independent Investors SA claimed a loss of $5.95 million on its investment in Fiserv [2]. - Fiserv's shares have declined by 38% this year, indicating significant financial distress for the company [6]. Group 3: Legal Process - The selection of a lead shareholder plaintiff is influenced by the size of the investor's losses and the capability of their attorneys to manage the litigation, as per the 1995 Private Securities Litigation Reform Act [3]. - The pension fund for police officers in Hollywood, Florida, manages approximately $460 million, while Ethenea Independent Investors SA manages about €2.4 billion ($2.8 billion) in assets [7].

Core Viewpoint - The article discusses ongoing legal investigations into Molina Healthcare, Inc. regarding potential violations of federal securities laws, encouraging affected investors to seek legal counsel and participate in a class action lawsuit [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is investigating potential claims against Molina Healthcare and reminds investors of the December 2, 2025 deadline to seek the role of lead plaintiff in a federal securities class action [2][4]. - The complaint alleges that Molina and its executives made false and misleading statements regarding the company's financial health and operational challenges [3][4]. Group 2: Financial Performance and Stock Impact - On July 7, 2025, Molina announced second-quarter financial results, revealing adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures [5]. - Following this announcement, Molina's stock price fell by $6.97, or 2.9%, closing at $232.61 per share on July 7, 2025 [5]. - On July 23, 2025, Molina further slashed its full-year 2025 earnings guidance, reporting a GAAP net income of $4.75 per diluted share for the second quarter, an 8% decrease year over year [6]. - This guidance cut represented a 13.6% reduction at the midpoint, with full-year GAAP net income guidance cut by 27% to $912 million [6][7]. - Following the second guidance cut, Molina's stock price plummeted by $32.03, or 16.84%, closing at $158.22 per share on July 24, 2025 [7]. Group 3: Company Challenges - The complaint highlights several material adverse facts, including issues with medical cost trend assumptions and a dislocation between premium rates and medical costs, which have negatively impacted Molina's financial outlook [4]. - Molina's near-term growth is reportedly dependent on reduced utilization of various health services, indicating significant operational challenges [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against CTO Realty Growth, Inc. due to allegations of misleading statements regarding the sustainability of dividends and financial practices [4][6]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses in CTO between February 18, 2021, and June 24, 2025, to discuss their legal rights [1][4]. - There is a deadline of October 7, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against CTO [4][8]. Group 2: Allegations Against CTO - The complaint alleges that CTO and its executives violated federal securities laws by making false statements and failing to disclose critical financial information [6]. - Specific allegations include that CTO's dividends were less sustainable than claimed, and that deceptive practices were used to inflate its Adjusted Funds From Operations (AFFO) [6][7]. Group 3: Financial Concerns - A report by Wolfpack Research criticized CTO for not generating enough cash to cover its recurring capital expenditures and dividends since converting to a REIT in 2021 [7]. - The report highlighted that CTO increased its shares outstanding by 70% since December 2022 to cover a $38 million dividend shortfall from 2021 to 2024 [7]. - CTO's financial situation is precarious, with only $8.4 million in cash against quarterly dividends of $14 million and average recurring capital expenditures of $5.7 million [7]. Group 4: Market Reaction - Following the release of the Wolfpack Report, CTO's stock price fell by $0.98 per share, or 5.42%, closing at $17.10 per share on June 25, 2025 [8].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In PubMatic To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in PubMatic between February 27, 2025 and August 11, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) -- Far ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nutex To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Nutex between August 8, 2024 and August 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) -- Faruqi & Far ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Savara To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Savara between March 7, 2024 and May 23, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruq ...

If you suffered losses in LifeMD between May 7, 2025 and August 5, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330Â (Ext. 1310). Accessibility StatementSkip Navigation Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In LifeMD To Contact Him Directly To Discuss Their Options [You may also click here for additional information] NEW YORK, Oct. 2, 2025 /PRNewswire/ ...

Accessibility StatementSkip Navigation The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by th ...